Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.67 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.58 |
| ▸ | GCGR | P47871 | 3/20 | 0.58 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.58 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.58 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.58 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.55 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.52 |
| ▸ | RELA | Q04206 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.50 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5475289 | 1.00 | ALDH1A1 (0.67) | ALDH1A1MAPK1MAPK13GCGRMAPK12 | |
| SCHEMBL18748039 | 0.91 | MAPK1 (0.61) | ALDH1A1MAPK1MAPK13GCGRMAPK12 | |
| SCHEMBL18748037 | 0.91 | MAPK1 (0.61) | ALDH1A1MAPK1MAPK13GCGRMAPK12 | |
| SCHEMBL16659835 | 0.89 | TDP1 (0.66) | ALDH1A1MAPK1MAPK13GCGRMAPK12 | |
| SCHEMBL30476324 | 0.89 | L3MBTL1 (0.64) | ALDH1A1MAPK1MAPK13GCGRMAPK12 | |
| SCHEMBL650086 | 0.89 | L3MBTL1 (0.64) | ALDH1A1MAPK1MAPK13GCGRMAPK12 | |
| SCHEMBL23511350 | 0.87 | ALDH1A1 (0.56) | ALDH1A1MAPK1MAPK13GCGRMAPK12 | |
| SCHEMBL18758213 | 0.85 | MAPK13 (0.54) | ALDH1A1MAPK1MAPK13GCGRMAPK12 | |
| SCHEMBL31599316 | 0.84 | ALDH1A1 (0.56) | ALDH1A1MAPK1ADORA2AADORA1SMN1; SMN2 | |
| SCHEMBL30395001 | 0.84 | ALDH1A1 (0.56) | ALDH1A1MAPK1ADORA2AADORA1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9324951-B2 | Pyrazine derivative, and light emitting element, display device, electronic device using the pyrazine derivative | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2016-04-26 | — | — | US | disclosed |
| US-9324951-B2 | Pyrazine derivative, and light emitting element, display device, electronic device using the pyrazine derivative | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2016-04-26 | — | — | US | disclosed |
| US-9324951-B2 | Pyrazine derivative, and light emitting element, display device, electronic device using the pyrazine derivative | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2016-04-26 | — | — | US | disclosed |
| US-20150112065-A1 | Pyrazine Derivative, and Light Emitting Element, Display Device, Electronic Device Using the Pyrazine Derivative | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. | 2015-04-23 | — | — | US | disclosed |
| US-20150112065-A1 | Pyrazine Derivative, and Light Emitting Element, Display Device, Electronic Device Using the Pyrazine Derivative | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. | 2015-04-23 | — | — | US | disclosed |
| US-20150112065-A1 | Pyrazine Derivative, and Light Emitting Element, Display Device, Electronic Device Using the Pyrazine Derivative | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. | 2015-04-23 | — | — | US | disclosed |
| US-8920941-B2 | Pyrazine derivative, and light emitting element, display device, electronic device using the pyrazine derivative | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2014-12-30 | — | — | US | disclosed |
| US-8920941-B2 | Pyrazine derivative, and light emitting element, display device, electronic device using the pyrazine derivative | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2014-12-30 | — | — | US | disclosed |
| US-8920941-B2 | Pyrazine derivative, and light emitting element, display device, electronic device using the pyrazine derivative | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2014-12-30 | — | — | US | disclosed |
| US-20070161793-A1 | Pyrazine derivative, and light emitting element, display device, electronic device using the pyrazine derivative | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2007-07-12 | — | — | US | disclosed |
| US-20070161793-A1 | Pyrazine derivative, and light emitting element, display device, electronic device using the pyrazine derivative | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2007-07-12 | — | — | US | disclosed |
| US-20070161793-A1 | Pyrazine derivative, and light emitting element, display device, electronic device using the pyrazine derivative | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161793-A1 | Pyrazine derivative, and light emitting element, display device, electronic device using the pyrazine derivative | GRIA1, GRIN1, GRIA2 | ALDH1A1 336/4885MAPK1 901/4885MAPK13 3548/4885 |
| US-20150112065-A1 | Pyrazine Derivative, and Light Emitting Element, Display Device, Electronic Device Using the Pyrazine Derivative | GRIA1, GRIN1, GRIA2 | ALDH1A1 336/4885MAPK1 901/4885MAPK13 3548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.